CCDC167 as a potential therapeutic target and regulator of cell cycle-related networks in breast cancer

• DOI: 10.18632/aging.202382
• Publication Date: 2021-01-10T12:51:01Z
• Authors: Pin-Shern Chen; Hui-Ping Hsu; Nam Nhut Phan; Meng-Chi Yen; Feng-Wei Chen; Yu-Wei Liu; Fang-Ping Lin; Sheng-Yao Feng; Tsung-Lin Cheng; Pei-Hsiang Yeh; Hany A. Omar; Zhengda Sun; Jia-Zhen Jiang; Yi-Shin Chan; Ming-Derg Lai; Chih-Yang Wang; Jui-Hsiang Hung
• Keywords: Master regulator

According to cancer statistics reported in 2020, breast constitutes 30% of new cases diagnosed American women. Histological markers are expressions the estrogen receptor (ER), progesterone (PR), and human epidermal growth factor (HER)-2. Up 80% cancers grouped as ER-positive, which implies a crucial role for development. Therefore, identifying potential therapeutic targets investigating their downstream pathways networks extremely important drug development these patients. Through high-throughput technology bioinformatics screening, we revealed that coiled-coil domain-containing protein 167 (CCDC167) was upregulated different types tumors; however, CCDC167 still remains unclear. Integrating many kinds databases including ONCOMINE, MetaCore, IPA, Kaplan-Meier Plotter, found high expression levels predicted poor prognoses Knockdown attenuated aggressive proliferation. We also demonstrated treatment with fluorouracil, carboplatin, paclitaxel, doxorubicin resulted decreased suppressed MCF-7 cells. Collectively, findings suggest has target cancer.